Page 544 - Basic _ Clinical Pharmacology ( PDFDrive )

530 SECTION V Drugs That Act in the Central Nervous System

REFERENCES Kane JM et al: Overview of short- and long-term tolerability and safety of brexpip-
razole in patients with schizophrenia. Schizophr Res 2016;174:93.
Antipsychotic Drugs Karam CS et al: Signaling pathways in schizophrenia: Emerging targets and thera-
Bhattacharjee J, El-Sayeh HG: Aripiprazole versus typical antipsychotic drugs for peutic strategies. Trend Pharmacol Sci 2010;31:381.
schizophrenia. Cochrane Database Syst Rev 2008;16(3):CD006617. Lao KS et al: Tolerability and safety profile of cariprazine in treating psychotic
Caccia S et al: A new generation of antipsychotics: Pharmacology and clinical disorders, bipolar disorder and major depressive disorder: a systematic
utility of cariprazine in schizophrenia. Ther Clin Risk Manag 2013;9:319. review with meta-analysis of randomized controlled trials. CNS Drugs
2016;30:1043.
Chue P: Glycine reuptake inhibition as a new therapeutic approach in schizo-
phrenia: Focus on the glycine transporter 1 (GlyT1). Curr Pharm Des Lieberman JA et al: Antipsychotic drugs: Comparison in animal models of effi-
2013;19:1311. cacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev
2008;60:358.
Citrome L: A review of the pharmacology, efficacy and tolerability of recently
approved and upcoming oral antipsychotics: An evidence-based medicine Lieberman JA et al: Effectiveness of antipsychotic drugs in patients with chronic
approach. CNS Drugs 2013;27:879. schizophrenia. N Engl J Med 2005;353:1209.
Citrome L: Cariprazine: Chemistry, pharmacodynamics, pharmacokinetics, and McKeage K, Plosker GL: Amisulpride: A review of its use in the management of
metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug schizophrenia. CNS Drugs 2004;18:933.
Metab Toxicol 2013;9:193. Meltzer HY: Treatment of schizophrenia and spectrum disorders: Pharmaco-
Citrome L: Cariprazine in bipolar disorder: Clinical efficacy, tolerability, and place therapy, psychosocial treatments, and neurotransmitter interactions. Biol
in therapy. Adv Ther 2013;30:102. Psychiatry 1999;46:1321.
Citrome L: Cariprazine in schizophrenia: Clinical efficacy, tolerability, and place in Meltzer HY, Massey BW: The role of serotonin receptors in the action of atypical
therapy. Adv Ther 2013;30:114. antipsychotic drugs. Curr Opin Pharmacol 2011;11:59.
Correll CU et al: Efficacy of brexpiprazole in patients with acute schizophrenia: Meltzer HY et al: A randomized, double-blind comparison of clozapine and high-
Review of three randomized, double-blind, placebo-controlled studies. dose olanzapine in treatment-resistant patients with schizophrenia. J Clin
Schizophr Res 2016;174:82. Psychiatry 2008;69:274.
Coyle JT: Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cell Newcomer JW, Haupt DW: The metabolic effects of antipsychotic medications.
Mol Neurobiol 2006;26:365. Can J Psychiatry 2006;51:480.
Durgam S et al: An 8-week randomized, double-blind, placebo-controlled evalua- Pimavanserin (Nuplazid) for Parkinson’s disease psychosis. Med Lett Drugs Ther
tion of the safety and efficacy of cariprazine in patients with bipolar I depres- 2016;58:74.
sion. Am J Psychiatry 2016;173:271. Schwarz C et al: Valproate for schizophrenia. Cochrane Database Syst Rev
Durgam S et al: Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, 2008;3:CD004028.
phase 3, randomized, double-blind, placebo- and active-controlled trial. J Urichuk L et al: Metabolism of atypical antipsychotics: Involvement of cytochrome
Clin Psychiatry 2015;76:e1574. p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab
Escamilla MA, Zavala JM: Genetics of bipolar disorder. Dialogues Clin Neurosci 2008;9:410.
2008;10:141. Walsh T et al: Rare structural variants disrupt multiple genes in neurodevelopmen-
Fava M et al: Adjunctive brexpiprazole in patients with major depressive disorder tal pathways in schizophrenia. Science 2008;320:539.
and irritability: an exploratory study. J Clin Psychiatry 2016;77:1695. Zhang A, Neumeyer JL, Baldessarini RJ: Recent progress in development of dopa-
Fountoulakis KN, Vieta E: Treatment of bipolar disorder: A systematic review mine receptor subtype-selective agents: Potential therapeutics for neurologi-
of available data and clinical perspectives. Int J Neuropsychopharmacol cal and psychiatric disorders. Chem Rev 2007;107:274.
2008;11:999.
Freudenreich O, Goff DC: Antipsychotic combination therapy in schizophrenia: Mood Stabilizers
A review of efficacy and risks of current combinations. Acta Psychiatr Scand
2002;106:323. Baraban JM, Worley PF, Snyder SH: Second messenger systems and psychoac-
Glassman AH: Schizophrenia, antipsychotic drugs, and cardiovascular disease. tive drug action: Focus on the phosphoinositide system and lithium. Am J
Psychiatry 1989;146:1251.
J Clin Psychiatry 2005;66(Suppl 6):5.
Grunder G, Nippius H, Carlsson A: The “atypicality” of antipsychotics: A concept Bowden CL, Singh V: Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr
Scand Suppl 2005;426:13.
re-examined and re-defined. Nat Rev Drug Discov 2009;8:197.
Haddad PM, Anderson IM: Antipsychotic-related QTc prolongation, torsade de Catapano LA, Manji HK: Kinases as drug targets in the treatment of bipolar dis-
order. Drug Discov Today 2008;13:295.
pointes and sudden death. Drugs 2002;62:1649.
Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuro- Fountoulakis KN, Vieta E: Treatment of bipolar disorder: A systematic review
of available data and clinical perspectives. Int J Neuropsychopharmacol
pathology: On the matter of their convergence. Mol Psychiatry 2005;10:40. 2008;11:999.
Hashimoto K et al: Glutamate modulators as potential therapeutic drugs in Jope RS: Anti-bipolar therapy: Mechanism of action of lithium. Mol Psychiatry
schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 1999;4:117.
2013;263:367.
Herman EJ et al: Metabotropic glutamate receptors for new treatments in schizo- Mathew SJ, Manji HK, Charney DS: Novel drugs and therapeutic targets for
severe mood disorders. Neuropsychopharmacology 2008;33:2080.
phrenia. Handb Exp Pharmacol 2012;213:297.
Hermanowicz S, Hermanowicz N: The safety, tolerability and efficacy of pimavan- Quiroz JA et al: Emerging experimental therapeutics for bipolar disorder: Clues
from the molecular pathophysiology. Mol Psychiatry 2004;9:756.
serin tartrate in the treatment of psychosis in Parkinson’s disease. Expert Rev
Neurother 2016;16:625. Vieta E, Sanchez-Moreno J: Acute and long-term treatment of mania. Dialogues
Hovelsø N et al: Therapeutic potential of metabotropic glutamate receptor modu- Clin Neurosci 2008;10:165.
lators. Curr Neuropharmacol 2012;10:12. Yatham LN et al: Third generation anticonvulsants in bipolar disorder: A review
Javitt DC: Glycine transport inhibitors in the treatment of schizophrenia. Handb of efficacy and summary of clinical recommendations. J Clin Psychiatry
2002;63:275.
Exp Pharmacol 2012;213:367.